Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Analysts

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has received an average rating of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company.

BIOVF has been the topic of several recent analyst reports. Pareto Securities cut Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd.

Swedish Orphan Biovitrum Stock Performance

BIOVF opened at $48.13 on Friday. The firm’s fifty day moving average is $48.38 and its two-hundred day moving average is $45.39. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The firm has a market cap of $17.13 billion, a PE ratio of 106.95 and a beta of 0.33. Swedish Orphan Biovitrum has a twelve month low of $29.18 and a twelve month high of $49.03.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.